Antimycobacterial activity of luteolin in resistant Mycobacterium tuberculosis isolates and cytotoxicity on L929 cells

Basit Öğe Kaydı
dc.contributor.authorAydin, Elif
dc.contributor.authorGunduz, Meliha Koldemir
dc.contributor.authorKaymak, Gullu
dc.contributor.authorSezgin, Ayse Kocak
dc.contributor.authorDaggez, Halime
dc.contributor.authorRenders, Duygu Percin
dc.contributor.authorYakupogullari, Yusuf
dc.date.accessioned2026-04-04T13:34:55Z
dc.date.available2026-04-04T13:34:55Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractMycobacterium tuberculosis (M. tuberculosis) bacteria can cause oxidative stress and the production of inflammatory cytokines, creating an environment that enhances tumour formation, progression and metastasis. Epidemiological studies have found a link between lung cancer and tuberculosis (TB), but the cellular mechanism is still unclear. Current treatment involves multiple drugs and a long treatment regimen. The fact that there is a very limited number of anti-tuberculosis (anti-TB) drugs against TB, that no antimicrobial has been developed that can treat TB alone, and therefore, if a pathogen with such limited treatment options develops resistance to existing drugs, treatment success is significantly reduced. As a result, it is very important to develop new and alternative drugs against this important pathogen that can shorten the duration of treatment and increase anti-TB immunity during the treatment phase. In this study, we show that Luteolin (LUT), a plant-based flavonoid, exhibits anti-TB activity with a MIC value of 100 mu g/mL when applied alone to control strain and resistant clinical isolates. In addition, a suppressive effect of 6.11 mu g/mL LUT on lung cancer cells, as well as a protective and regulatory effect on the function of the antioxidant system, the activity of oxidative metabolism enzymes and inflammation were shown. Therefore, the use of LUT in conventional antibiotic therapy may provide a means to prevent the development of drug resistance and improve disease outcomes.
dc.identifier.doi10.1016/j.micpath.2025.107287
dc.identifier.issn0882-4010
dc.identifier.issn1096-1208
dc.identifier.orcid0000-0002-5545-3467
dc.identifier.orcid0000-0002-1510-2937
dc.identifier.orcid0000-0002-6777-6730
dc.identifier.orcid0000-0003-0877-453X
dc.identifier.pmid39800168
dc.identifier.scopus2-s2.0-85215098014
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.micpath.2025.107287
dc.identifier.urihttps://hdl.handle.net/11616/109496
dc.identifier.volume200
dc.identifier.wosWOS:001401853800001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAcademic Press Ltd- Elsevier Science Ltd
dc.relation.ispartofMicrobial Pathogenesis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectLung
dc.subjectSensitization
dc.subjectPathway
dc.titleAntimycobacterial activity of luteolin in resistant Mycobacterium tuberculosis isolates and cytotoxicity on L929 cells
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu